why choose us

Clinical Trials Search

Showing 14,550 of 132,963 result(s)
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Status: Completed

Condition: Advanced Cholangiocarcinoma

Interventions: Undergo collection of blood samples

Date: 2023-03-06

Solriamfetol and CBT-I in Patients With Insomnia Disorder

Status: Completed

Condition: Insomnia

Interventions: Solriamfetol (trade name Sunosi), is a norepinephrine-dopamine reuptake inhibitor available in 75mg and 150mg tablets for oral administration during t

Date: 2023-03-06

A Study of NT 201 Doses in the Treatment of Platysma Prominence

Status: ACTIVE_NOT_RECRUITING

Condition: Platysma Prominence

Interventions: Clostridium botulinum neurotoxin type A (150 kiloDalton [kD], free of complexing proteins) powder for solution for injection.

Date: 2023-03-06

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Status: NOT_YET_RECRUITING

Condition: Treatment Resistant Depression

Interventions: Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)

Date: 2023-03-06

Healthy Mom Zone Gestational Weight Gain Management Intervention 2.0

Status: Completed

Condition: Gestational Weight Gain

Interventions: The intervention may be adapted such that a woman receives more support with each adaptation (only women who need added support to regulate GWG will r

Date: 2023-03-06

Maternal Stress and Blood Sugar Metabolization

Status: Completed

Condition: Pregnancy

Interventions:

Date: 2023-03-06

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Status: Completed

Condition: Polymyalgia Rheumatica

Interventions: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen

Date: 2023-03-06

A Study of BDTX-4933 in Patients With BRAF and Select RAS;MAPK Mutation-Positive Cancers

Status: Completed

Condition: Non-small Cell Lung Cancer

Interventions: RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active KRAS or NRAS mutations

Date: 2023-03-06

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Status: COMPLETED

Condition: Venous Thromboembolism

Interventions: patients treated with apixaban

Date: 2023-03-06